Varian Halcyon Treatment System Receives China NMPA Approval

Thursday, November 29, 2018 Cancer News
Email Print This Page Comment bookmark
Font : A-A+

PALO ALTO, Calif., Nov. 28, 2018 /PRNewswire/ -- Varian (NYSE: VAR) today announced its Halcyon system has

been approved by the China National Medical Product Administration (NMPA), which allows the company to market this new cancer treatment system in China.  This approval further expands the global availability of Halcyon and access to high-quality, cost-effective
cancer treatments.

As an advanced cancer treatment system with a human-centered and user-friendly design, Halcyon is engineered to revolutionize clinical workflow, accelerate installation timeframes, expedite commissioning, simplify training, and automate treatment. The system is well suited to treat cancer patients with radiotherapy, offering advanced treatments for lung, prostate, breast, head & neck, and many other forms of cancer.

"We are very excited to further expand Halcyon's global availability," said Chris Toth, president Varian Oncology Systems.  "With the most recent announcement by the Chinese government for expanding Category B licenses and enabling County hospital oncology services availability, Halcyon is a perfect fit."

Halcyon has already received FDA 510(k) clearance in the US, CE mark in Europe, Shonin approval in Japan, ANVISA registration in Brazil, Atomic Energy Regulatory Board (AERB) Certificate for Import and Supply as well as Type Approval in India and TFDA approval in Taiwan since its launch in May 2017.

For more information on Halcyon visit www.varian.com/halcyon.

About Varian Varian is a leader in developing and delivering cancer care solutions and is focused on creating a world without fear of cancer. Headquartered in Palo Alto, California, Varian employs approximately 7,000 people around the world. For more information, visit http://www.varian.com and follow @VarianMedSys on Twitter.

Press ContactMark PlungyDirector, Public Relations+1 (650) 424-5630 mark.plungy@varian.com

Investor Relations ContactJ. Michael BruffVice President, Investor Relations+1 (650) 424-5163 mike.bruff@varian.com

 

Cision View original content:http://www.prnewswire.com/news-releases/varian-halcyon-treatment-system-receives-china-nmpa-approval-300756966.html

SOURCE Varian



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store